Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/17458
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | The Australian Cancer Anaemia Survey: a snapshot of anaemia in adult patients with cancer |
Author: | Seshadri, T. Prince, H. Bell, D. Coughlin, P. James, P. Richardson, G. Chern, B. Briggs, P. Norman, J. Olver, I. Karapetis, C. Stewart, J. |
Citation: | Medical Journal of Australia, 2005; 182(9):453-457 |
Publisher: | Australasian Med Publ Co Ltd |
Issue Date: | 2005 |
ISSN: | 0025-729X 1326-5377 |
Statement of Responsibility: | Tara Seshadri, H Miles Prince, David R Bell, Paul B Coughlin, Philip P B James, Gary E Richardson, Boris Chern, Peter Briggs, John Norman, Ian N Olver, Chris Karapetis and John Stewart, for the Australia Cancer Anaemia Study (ACAS) Group |
Abstract: | Objective: To evaluate the frequency and management of anaemia in Australian adults with solid and haematological malignancies. Design: 6-month observational, prospective, multicentre study. Participants: 694 patients recruited from outpatient oncology clinics in 24 hospitals in five Australian states between 9 April 2001 and 31 July 2001. Main outcome measures: Frequency of anaemia (haemoglobin [Hb] level < 120 g/L) at enrolment and over ensuing 6 months, by tumour type, disease status and cancer treatment; anaemia treatment and “trigger” Hb level for this treatment. Results: Participants had median age 60 years, and 61% were women. Prevalence of anaemia at enrolment was 35% (199/562), with 78% of these 199 having mild anaemia (Hb, 100–119 g/L). Frequency of anaemia (either present at enrolment or developing during the study) was 57% overall (323/566), and varied with tumour type, from 49% (lymphoma/myeloma) to 85% (urogenital cancer). Patients who received radiotherapy either in combination or concomitant with chemotherapy were more likely to have anaemia (73%) than those receiving chemotherapy alone (58%) (P = 0.004). Of all chemotherapy patients not anaemic at enrolment, 23% developed anaemia by the second monthly follow-up. Independent predictors for anaemia in chemotherapy patients were low baseline Hb level (odds ratio [OR], 5.4; 95% CI, 2.7–10.9) and use of platinum chemotherapeutic agents (OR, 4.8; 95% CI, 2.1–11.4) (P < 0.001). Anaemia was treated in 41% of patients with anaemia at enrolment — by transfusion (36%), iron (5%) and erythropoietic agents (2%). Frequency of anaemia treatment varied between tumour types, from 19% (breast cancer) to 60% (leukaemia). The mean “trigger Hb” for initiating transfusion was 95 g/L. Conclusions: Anaemia is prevalent among Australian patients with cancer managed in hospital oncology units. Its management varies between tumour types. Many patients do not receive treatment for their anaemia. |
Keywords: | Australian Cancer Anaemia Study Group Humans Neoplasms Anemia Incidence Prevalence Statistics, Nonparametric Prospective Studies Adult Aged Aged, 80 and over Middle Aged Australia Female Male |
Description: | The document attached has been archived with permission from the editor of the Medical Journal of Australia (09 January 2008). An external link to the publisher’s copy is included. |
DOI: | 10.5694/j.1326-5377.2005.tb06784.x |
Published version: | http://www.mja.com.au/public/issues/182_09_020505/ses10667_fm.html |
Appears in Collections: | Aurora harvest 2 Medicine publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
hdl_17458.pdf | Published version | 255.92 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.